Morgan Stanley’s Neos Therapeutics, Inc NEOS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2021
Q1 | – | Sell |
-1,250
| Closed | -$1K | – | 7661 |
|
|
2020
Q4 | $1K | Buy |
1,250
+200
| +19% | +$124 | ﹤0.01% | 7015 |
|
|
2020
Q3 | $1K | Buy |
1,050
+750
| +250% | +$510 | ﹤0.01% | 6705 |
|
|
2020
Q2 | $0 | Hold |
300
| – | – | ﹤0.01% | 6825 |
|
|
2020
Q1 | $0 | Hold |
300
| – | – | ﹤0.01% | 6826 |
|
|
2019
Q4 | $0 | Sell |
300
-1,300
| -81% | -$1.95K | ﹤0.01% | 6864 |
|
|
2019
Q3 | $2K | Sell |
1,600
-416,552
| -100% | -$674K | ﹤0.01% | 6510 |
|
|
2019
Q2 | $539K | Buy |
418,152
+117,678
| +39% | +$216K | ﹤0.01% | 4574 |
|
|
2019
Q1 | $784K | Buy |
300,474
+223,719
| +291% | +$525K | ﹤0.01% | 4270 |
|
|
2018
Q4 | $127K | Buy |
76,755
+24,331
| +46% | +$68.3K | ﹤0.01% | 5459 |
|
|
2018
Q3 | $255K | Sell |
52,424
-13,683
| -21% | -$77.6K | ﹤0.01% | 5340 |
|
|
2018
Q2 | $413K | Buy |
66,107
+4,260
| +7% | +$31.8K | ﹤0.01% | 5223 |
|
|
2018
Q1 | $513K | Buy |
61,847
+2,205
| +4% | +$21.1K | ﹤0.01% | 4989 |
|
|
2017
Q4 | $608K | Buy |
59,642
+20,395
| +52% | +$196K | ﹤0.01% | 4861 |
|
|
2017
Q3 | $359K | Buy |
39,247
+14,315
| +57% | +$109K | ﹤0.01% | 5063 |
|
|
2017
Q2 | $182K | Sell |
24,932
-5,693
| -19% | -$43K | ﹤0.01% | 5379 |
|
|
2017
Q1 | $221K | Sell |
30,625
-16,397
| -35% | -$102K | ﹤0.01% | 5281 |
|
|
2016
Q4 | $275K | Buy |
47,022
+36,305
| +339% | +$246K | ﹤0.01% | 5221 |
|
|
2016
Q3 | $71K | Buy |
10,717
+7,817
| +270% | +$61.9K | ﹤0.01% | 5451 |
|
|
2016
Q2 | $27K | Sell |
2,900
-948
| -25% | -$9.04K | ﹤0.01% | 5751 |
|
|
2016
Q1 | $42K | Sell |
3,848
-958
| -20% | -$10.1K | ﹤0.01% | 5684 |
|
|
2015
Q4 | $69K | Buy |
4,806
+1,403
| +41% | +$21.2K | ﹤0.01% | 5594 |
|
|
2015
Q3 | $71K | Buy |
+3,403
| New | +$75K | ﹤0.01% | 5585 |
|
Morgan Stanley's NEOS Position: Q1 2021 in Review
Morgan Stanley sold out of Neos Therapeutics, Inc (NEOS) in Q1 2021, closing a stake of 1,250 shares — an estimated $1K sold.
Morgan Stanley first reported a position in NEOS in Q3 2015 and held it in 22 quarters. The position peaked at $784K in Q1 2019. 0 funds tracked by Wall St. Rank hold NEOS as of Q1 2021.
- Morgan Stanley reported no remaining Neos Therapeutics, Inc position as of Q1 2021 after selling out during the quarter.
- Morgan Stanley sold 1,250 Neos Therapeutics, Inc shares in Q1 2021, an estimated $1K.
- Morgan Stanley first reported a position in Neos Therapeutics, Inc in Q3 2015 and held it in 22 quarters.
- Morgan Stanley's Neos Therapeutics, Inc position peaked at $784K in Q1 2019.
- 0 funds tracked by Wall St. Rank held Neos Therapeutics, Inc as of Q1 2021.
Based on Morgan Stanley's 13F filing for Q1 2021, filed 17 May 2021.